Complications and risks of the surgery of tumors of the upper digestive tract (Foregut)
Part I: Esophagus

Česká verzia

Authors: M. Duda ^1,2; L. Adamčík ²; M. Škrovina ²; T. Jínek ²
Authors place of work: II. chirurgická klinika FN a LFUP Olomouc, přednosta: Prof. MUDr. Petr Bachleda, CSc ¹; Chirurgické oddělení nemocnice a KOC Nový Jičín, primář: MUDr. M. Škrovina, Ph. D. ²
Published in the journal: Rozhl. Chir., 2013, roč. 92, č. 9, s. 523-529.
Category: Various Specialization

Práce je určena k postgraduálnímu vzdělávání lékařů.

Summary

Introduction:
The aim of the work is to evaluate acceptable mortality and morbidity associated with the esophageal resections for carcinoma.

Method:
The work analyses the data of patients with esophageal cancer from the Czech National Cancer Registry and it compares personal experience with complications and risks associated with the esophagectomy for carcinoma with the data from specialized literature published in recent years.

Results:
Despite improvements in the surgical technique and the perioperative intensive care, the esophagectomy maintains a relatively high morbidity and mortality. Published studies present mortality up to 10% and total morbidity between 40–60%. Respiratory complications are most frequent and significant and they reach up to 40% and the anastomotic dehiscence ranges from 0 to 25%. At the authors’ workplace in Nový Jičín, a total of 193 patients with the esophageal carcinoma were examined since 2007; 38% of these patients were indicated for operation and 62 esophageal resections with replacement were performed. The postoperative mortality within 30 days was 3.2% and the total morbidity was approximately 50%. Respiratory and cardiac complications were 28% and 18% respectively, fistula in the cervical anastomosis was seen in 5% and in the gastric tube in 3%, only one patient died from this surgical complication. The paralysis of the recurrent nerve occurred in 10%, and chylothorax in 3%. In almost all patients, the operation began with a laparoscopic revision to confirm operability and in 37% of the operated patients a video-assisted approach was used, most often the thoracoscopic mobilization of the esophagus.

Conclusion:
The surgical treatment of tumors of the esophagus is a highly specialized domain of thoracic surgeons specialized in the issuesof the esophagus. General trends for improving the morbidity and mortality include the use of minimally-invasive approaches, fast-track programs after the esophagectomy, and the application of principles of High-volume centres. The long-term prognosis of patients with esophageal cancer is principally dependent on the degree of advancement of the disease

Key words:
esophageal carcinoma – complications – risks – results

Zdroje

1. Dušek L, et al. Czech cancer care in number 2008–2009. Praha, Grada 2009.

2. Duda M, Žaloudík J, Ryska M, Dušek L. Chirurgická léčba solidních nádorů v České republice. Rozhl Chir 2010;89:588–593.

3. Duda M, Adamčík L, Dušek L, Škrovina M, Jínek T. Zhoubné nádory jícnu v České republice. Rozhl Chir 2012;91:132–140.

4. Duda M, a kol. Jícen: pohled z mnoha úhlů v zrcadle zkušeností olomoucké jícnové školy. Olomouc, Universita Palackého Olomouc 2. vyd. 2012. http://eportal.chirurgie.upol.cz/ebook/

5. Duda M, Ryska M, Dušek L, Adamčík L, Škrovina M, et al. Nádory žaludku v České republice. Koncept „foregut surgery“. In: Ryska M, Zavoral M. editoři. Neoplázie žaludku. Sylaby přednášek XXII. Jarní setkání loket 2013, 3. Postgraduální kurz společnosti pro gastrointestinální onkologii 29. 3. 2013 Loket nad Ohří. Praha, Společnost pro Gastrointestinální onkologii (SGO), 2013:9–16. http://eportal.chirurgie.upol.cz/ebook/

6. Webové stránky Národního onkologického registru (NOR) České Republiky, Systém pro vizualizaci onkologických dat (SVOD) www. cba.muni.cz/svod.

7. Neoral Č, Aujeský R, Král V, Klein J, Bohanes T, et al. Technika získání sentinelových uzlin u tumorů v oblasti distálního jícnu a žaludku. Rozhl Chir 2005;84:307–309.

8. Pazdro A. Maligní nádory jícnu. In: Pafko P a kol. Causae mortis v chirurgii na přelomu tisíciletí. Praha, Galen 2005:73–80.

9. Polanecký O, Pazdro A, Tvrdoň J, Teršíp T, Šmejkal P, et al. Paliativní ošetření karcinomu jícnu – naše zkušenosti. Rozhl Chir 2006;85:186–189.

10. Pafko P, Pazdro A. Radikální léčba karcinomu jícnu (abstrakt). Bulletin HPB 2008;16:14–16.

11. Tvrdoň J, Haruštiak T, Pazdro A, Teršíp T, Pafko P. Stenty – paliativní kurativní ošetření jícnu. Sedmileté zkušenosti chirurgického pracoviště. Rozhl Chir 2008;87:355–359.

12. Dostalík J, Guňková P, Martínek L, Richter V, Guňka I, et al. Optimální miniinvazivní přístup při náhradě jícnu žaludkem. Rozhl Chir 2009;88:422–424.

13. Neoral Č, Aujeský R, Král V. Náhrady jícnu tlustým střevem- zkušenosti se 109 případy. Rozhl Chir 2010;89:740–745.

14. Aujeský R, Neoral Č, Král V, Vrba R, Vomáčková K. Videoasistovaná resekce jícnu pro karcinom – desetileté zkušenosti. Rozhl Chir 2010;89:746–749.

15. Goldminc M, Maddern G, Le Prise E, Meunier B, Campion JP, et al. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993;80:370.

16. Chu KM, Law SYK, Fok M, Wong J. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. American J Surg 1997;174:320–324.

17. Biere SS, Maas KW, Bonavina L, et al. Traditional invasive vs. minimally invasive esophagectomy: a multi-center, randomized trial (TIME-trial). BMC Surg 2011;11:2.

18. Briez N, Piessen G, Bonnetain F, Brigand C, Carrere N, et all. Open versus laparoscopically assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial-the MIRO trial. BMC cancer 2011;11:310.

19. Dhungel B, Diggs BS, Hunter JG, et al. Patients and perioperative predictors of morbidity and mortality after esophagectomy: American College of Surgeons National Surgical Quality Improvement Program (ASC-NSQIP) 2005–2008. J Gastrointest Surg 2010;14:1492–1501.

20. Bailey SH, Bull DA, Harpole DH, et al. Outcomes after esophagectomy: a ten-year prospective cohort. Ann Th orac Surg 2003;75:217–222.

21. Wright CD, Kucharczuk JC, O’Brien SM, et al. Predictor of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model. J Thorac Cardiovasc Surg 2009;137:587–595.

22. Atkins BZ, Shah AS, Hutcheson KA, et al. Reducing hospital morbidity and mortality following esopohagectomy. 2004;78: 1170–1176.

23. Morita M, Nakanoko T, Fujinaka Y, et al. In-hospital mortality after a surgical resection for esophageal cancer: analyse of the associated factors and historical changes. Ann Surg Oncol 2011;18:1757–1765.

24. Zingg U, Smithers BM, Gotley DC, et al. Factor associated with postoperative pulmonary morbidity after esophagectomy for cancer. Ann Surg Oncol 2011;18:1460–1468.

25. Michelet P, D’Journo XB, Roch A, et al. Protective ventilation influences systemic inflammation after esophagectomy: a randomized controlled study. Anesthesiology 2006;105:911–919.

26. Casado D, Lopez F, Marti R. Perioperative fluid management and major respiratory complications in patiens undergoing esophagectomy. Dis Esophagus 2010;23:523–528.

27. Neal JM, Wilcox RT, Allen HW, Low DE. Near-total esophagectomy: the influence of standardized multimodal management and intraoperative fluid restriction. Reg Anesth Pain Med 2003;28. 328–334.

28. Robertson SA, Skipworth RJ, Clarke DL, et al. Ventilatory and intensive care requirements following oesophageal resection. Ann R Coll Surg Engl 2006;88:354–357.

29. Lanuti M, de Delva PE, Maher A, et al. Feasebility and outcomes of an early extubation policy after esophagectomy. Ann Torac Surg 2006;82:2037–2041.

30. Yap FH, Lau JY, Joynt GM, et al. Early extubation after transthoracic oesophagectomy. Hong Kong Med J 2003;9:98–102.

31. Černá M, Köcher M, Dlouhý M, Neoral Č, Gryga A, et al. FerX Ella esophageal covered stent. Acta Univ Palacki Olomouc Fac med 2000; 143:79–80.

32. Duda M, Adamčík L, Czudek S, Škrovina M, Velkoborský M, et al. Miniinvazivní řešení komplikací v jícnové chirurgii. Slovenská chirurgia 2010;7:21–24.

33. Černá M, Köcher M, Válek V, Černá M, Kozák J, et al. Léčba benigních píštělí jícnu krytými biodegradabilními stenty. První výsledky. Čes Radiol 2011;65:112–116.

34. Mamidanna R, Bottle A, Aylin P, Faiz O, Hanna GB. Short-term outcomes following open versus minimally invasive oesophagectomy for cancer in England: a population-based national study. Ann Surg 2012;225:197–203.

35. Ben-David K, Darosi GA, Cendan JC, Howard D, Rossides G, et al. Decreasing morbidity and mortality in 100 consecutive minimally invasive esophagectomies. Surg Endosc 2012;26:162–167.

36. Munitz V, Martinez-de Haro LF, Ortiz A, et al. Effectiveness of a written clinical pathway for endhanced recovery after transthoracic (Ivor Lewis) oesophagectomy. Br J Surg 2010;97:714–718.

37. Chen G, Wang Z, Liu XY, Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Yvor-Lewis esophagectomy. World J Surg 2007;31: 1107–1114.

38. Nakagawa S, Kanda T, Kosugi S, et al. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus aft er extend radical esophagectomy with three field lymphadectomy. J Am Coll Surg 2004;198:205–211.

39. Meredith KL, Weber JM, Turga KK, et al. Pathologic response after neoadjuvant therapy is the maior determinant of survival in patiens with esophageal cancer. Ann Surg Oncol 2010;17: 1129–1167.

40. Cuesta MA, Biere SSAY, van Berge Henegouwen MI, van der Peet DL. Randomised trial, Minimally Invasive Oesophagectomy versus open eosophagectomy for patients with resectable oesophaged cancer. J Thorac Dis 2012;4:462–464.

41. Clavien PA, Barkun J, de Oliviera ML, Michelle L, Vauthey JN, et all. The Clavien-Dindo classification of surical complications:five-year experience. Ann Surg 2009;250:187–196